Infliximab Therapy for 2 Patients with Vogt-Koyanagi-Harada Syndrome

Abstract

Purpose: To report the authors' experience using infliximab to treat 2 patients with Vogt-Koyanagi-Harada disease (VKH). Design: Interventional case series. Methods: Medical records of the 2 patients were reviewed. Results: After starting infliximab intravenous infusions, 5 mg/kg, both patients experienced rapid improvement in their VKH disease, and were able to taper and discontinue prednisone without disease recurrence for the several-month follow-up period. Conclusions: Infliximab may be effective treatment for VKH, and spares patients the side effects of corticosteroids and conventional immunosuppressive drugs.

KEYWORDS:

• infliximab
• tumor necrosis factor alpha
• uveitis
• Vogt-Koyanagi-Harada